Komori
Other Disclosures4883Modalis Therapeutics CorporationPharmaceuticals

Report on the Holding of a Company Information Session for Individual Investors and Release of the Materials Used

This is a report on the online company presentation for individual investors held on 19 May 2026, together with information on the presentation materials and video used at the event. Questions that were not answered will be addressed later on the FAQ page.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Launch date19 May 2026 (completed; date of the online company presentation)
Relationship between the counterparty and the company
Modalis Therapeutics Corporation4883
Relationship with the Company

The company operating the online company presentation for individual investors. The presentation video is posted on the SBI証券 website and official YouTube channel.

CounterpartySBI SECURITIES CO., LTD.
Location (as indicated in this announcement)

Chuo-ku, Tokyo (head office of 株式会社モダリス); Waltham, Massachusetts, United States (R&D facility)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Estimating the Prevalence of LAMA2 Congenital Muscular Dystrophy using Population Genetic Databases (2023), Myotonic Disease Foundation, DelveInsight, Okasan Securities, SkyQuest Industry Forecast 2023-2030, Report Ocean

Announced details
ItemDetails
CounterpartySBI SECURITIES CO., LTD.
Relationship with the CompanyThe company operating the online company presentation for individual investors. The presentation video is posted on the SBI証券 website and official YouTube channel.
Launch date19 May 2026 (completed; date of the online company presentation)
LocationChuo-ku, Tokyo (head office of 株式会社モダリス); Waltham, Massachusetts, United States (R&D facility)
SourceEstimating the Prevalence of LAMA2 Congenital Muscular Dystrophy using Population Genetic Databases (2023), Myotonic Disease Foundation, DelveInsight, Okasan Securities, SkyQuest Industry Forecast 2023-2030, Report Ocean
Items this document does not state (13)
Names of Products / Services CoveredCounterparty overviewContract ValueOffering priceContract DateApplicable areaAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To explain the Company’s business overview, development progress, future business strategy and financial strategy to individual investors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Report on the Holding of a Company Information Session for Individual Investors and Release of the Materials Used | Modalis Therapeutics Corporation (4883) timely disclosure | Komori